In Brief: Rogaine Rx-to-OTC switch

Rogaine Rx-to-OTC switch: Upjohn's NDA for switch of minoxidil from prescription to OTC status as a hair regrowth treatment for androgenetic alopecia scheduled for consideration by FDA's Nonprescription Drugs and Dermatologic Drugs Advisory Committees on Nov. 17. The meeting will be held beginning at 8 a.m. in conference rooms D & E of FDA's Parklawn Building...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

More from HBW Insight